General Information
Carbidopa, classified as a non-competitive decarboxylase inhibitor, is used in combination with the chemically related levodopa for the treatment of Parkinson’s disease or Parkinson-like symptoms (e.g. stiffness, shakiness, difficulty moving). Used alone, carbidopa has no effect on Parkinson’s symptoms. It is used to improve the effect of levodopa and reduce unwelcome side effects such as nausea. The drug works by preventing the breakdown of levodopa in the bloodstream, which allows more levodopa to enter the brain. Carbidopa has no anti-Parkinson effects by itself.
About the API
Systematic name
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
Trade name(s)
Lodosyn Appearance
Technology
Synthetic
Molecular Formula
C10H14N2O4
Molecular Weight
226.2291 g/mol (anhydrous)
Therapeutic category
Parkinson
Available formulations
Oral Liquid
Oral Solid
Oral Solid Long-Acting
Other Systemic
Regulations
Canada DMF
CEP
EU DMF
Japan DMF
Other
US DMF
Canada DMF
CEP
EU DMF
Japan DMF
Other
US DMF